The study of cutaneous microvascular endothelial cells has been severely constrained by difficulty in the isolation, purification and serial passage of these cells. Only a handful of laboratories in the world have mastered the techniques involved. Moreover, culture of human dermal microsvacular endothelial cells is extremely expensive, because of their requirements for high concentration of human serum. Our laboratories are acknowledge experts in cell culture of microvascular endothelial cells as well as other more easily obtained resident cells of the skin e.g. keratinocytes and fibroblasts.
The specific aims of this core are: 1) To provide a stable supply of freshly harvested adult and neonatal human skin to ESDRC investigators. 2) To isolate, purify and culture specific populations of resident cells of the skin, especially microvascular endothelial cells, as well as relevant cells from other tissues e.g. large vessel endothelial and smooth muscle cells. 3) To maintain and provide immortalized microvascular endothelial cell lines to ESDRC investigators. 4) To provide organ culture of human skin to ESDRC investigators for studies involving immunocytochemistry and in situ hybridization. 5) To provide pure cultures of other resident cells of skin such as keratinocytes, fibroblasts, and smooth muscle cells, as requested by ESDRC investigators. 6) To provide quality and cost control through bulk purchases of tissue and cell culture reagents. 7) To provide training to ESDRC investigators regarding techniques of cell culture, and isolation as well as skin organ culture. 8) To culture antibody producing hybridomas and purify these antibodies for ESDRC investigators.
|Arbiser, Jack L; Bonner, Michael Y; Gilbert, Linda C (2017) Targeting the duality of cancer. NPJ Precis Oncol 1:|
|Pleniceanu, Oren; Shukrun, Racheli; Omer, Dorit et al. (2017) Peroxisome proliferator-activated receptor gamma (PPAR?) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target EMBO Mol Med 9:508-530|
|Arbiser, Jack L; Bonner, Michael Y (2016) Seborrheic Keratoses: The Rodney Dangerfield of Skin lesions, and Why They Should Get Our Respect. J Invest Dermatol 136:564-566|
|Díaz, Begoña; Ostapoff, Katherine T; Toombs, Jason E et al. (2016) Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model. Oncotarget 7:51569-51580|
|Laidlaw, Kamilla M E; Berhan, Samuel; Liu, Suhu et al. (2016) Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia. Oncotarget 7:51651-51664|
|Bhandarkar, Sulochana S; Lanka, Padmavathy; Lanka, Lakshmana Rao et al. (2016) Tuberculosis verrucosa cutis lesions exhibit a greater microvessel count than lupus vulgaris lesions. Exp Dermatol 25:479-80|
|Costa, Adilson; Bonner, Michael Yi; Arbiser, Jack L (2016) Use of Polyphenolic Compounds in Dermatologic Oncology. Am J Clin Dermatol 17:369-85|
|Bonner, Michael Y; Karlsson, Isabella; Rodolfo, Monica et al. (2016) Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo. Oncotarget 7:12857-68|
|Arbiser, Jack L (2014) PHIPing out: a genetic basis for tumor ulceration. J Invest Dermatol 134:600-602|
|Spence-Shishido, Allyson; Carr, Christopher; Bonner, Michael Y et al. (2013) In vivo Gram staining of tinea versicolor. JAMA Dermatol 149:991-2|
Showing the most recent 10 out of 131 publications